- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05090384
Pediatric GVHD Low Risk Steroid Taper Trial
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
The standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of the donor immune cells using steroid medications such as prednisone. Although most GVHD, especially in children, responds well to treatment, sometimes (around 1/3 of the time) there is either no response to steroids or the response does not last. In those cases, the GVHD can become dangerous and even life-threatening. Unfortunately, doctors cannot predict who will have a good response to treatment based on symptom severity or initial response to steroids. As a result, nearly all children who develop GVHD are treated with long courses of high dose steroids even though that means many patients receive more treatment than they probably need. Steroid treatment can cause short-term complications like infections, high blood sugar, high blood pressure, muscle weakness, depression, anxiety, and problems sleeping and long-term complications like bone damage, cataracts in the eyes, and decreased growth. The risk of these complications increases with higher doses of steroids and longer treatment. It is important to find ways to decrease the steroid treatment in patients who do not need long courses.
The doctors conducting this research have developed a blood test (GVHD biomarkers) that predicts whether a patient will respond well to steroids. The study team found that children who have low GVHD biomarkers at the start of treatment and for the first two weeks of treatment have a very high response rate to steroids. In this study, the study team will monitor GVHD symptoms and biomarkers during treatment and taper steroids quickly in patients who have GVHD that is expected to respond very well to treatment. The study team will assess how many patients respond well to lower steroid dosing and what steroid complications develop. The study team will also use surveys to obtain the patient's own assessment of their quality of life (down to age 5 years).
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Rachel Young
- Phone Number: 212-659-5605
- Email: rachel.young@mssm.edu
Study Contact Backup
- Name: Janna Baez
- Phone Number: 212-241-0590
- Email: janna.baez@mssm.edu
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5S
- Not yet recruiting
- The Hospital for Sick Children
-
Contact:
- Muhammad Ali, MD
- Email: muhammad.ali@sickkids.ca
-
Principal Investigator:
- Muhammad Ali
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hospital of Los Angeles
-
Contact:
- Paibel Aguayo-Hiraldo, MD
- Phone Number: 323-361-1455
- Email: paguayohiraldo@chla.usc.edu
-
Principal Investigator:
- Paibel Aguayo-Hiraldo
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Children's Healthcare of Atlanta
-
Principal Investigator:
- Muna Qayed
-
Contact:
- Muna Qayed, MD, MS
- Phone Number: 404-785-1272
- Email: mqayed@emory.edu
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Andrew Harris, MD
- Email: harrisa7@mskcc.org
-
Principal Investigator:
- Andrew Harris
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- John Levine, MD, MS
- Phone Number: 212-241-1469
- Email: john.levine@mssm.edu
-
Principal Investigator:
- John E Levine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Not yet recruiting
- Children's Hospital of Philadelphia
-
Principal Investigator:
- Stephan Grupp
-
Contact:
- Stephan Grupp, MD
- Phone Number: 215-590-5476
- Email: grupp@email.chop.edu
-
-
Tennessee
-
Nashville, Tennessee, United States, 37235
- Recruiting
- Vanderbilt University Medical Center
-
Contact:
- Carrie Kitko, MD
- Phone Number: 800-811-8480
- Email: carrie.l.kitko@vumc.org
-
Principal Investigator:
- Carrie Kitko
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Newly diagnosed GVHD that meets criteria for Minnesota standard risk except GVHD that is limited to skin rash <50% body surface area (grade I GVHD) OR isolated upper gastrointestinal tract involvement
- Ann Arbor 1 GVHD by biomarkers
- GVHD not previously treated systemically (topical therapies and non-absorbed steroids are allowed)
- Any donor type, HLA-match, conditioning regimen is acceptable
- Age 0-21 years at the time of screening
- Performance score (Lansky/Karnofsky) ≥70%
- Signed and dated written informed consent obtained from patient or legal representative and assent from pediatric patients capable of providing assent
Exclusion Criteria:
- Patients treated for GVHD with >0.5 mg/kg prednisone or any steroid treatment for GVHD for more than 3 days prior to enrollment
- Patients receiving corticosteroids >0.1 mg/kg prednisone (or other steroid equivalent) for any indication within 7 days before the onset of acute GVHD except for adrenal insufficiency, premedication for transfusions/IV medications, or intermittent use for symptom control such as nausea/vomiting
- Relapsed, progressing, or persistent malignancy or other condition (e.g., known declining donor chimerism) requiring withdrawal of systemic immune suppression
- Patients with uncontrolled infection (i.e., progressive symptoms related to infection despite treatment, persistently positive microbiological cultures despite treatment, viral reactivations unresponsive to treatment, or any other evidence of severe infection)
- Severe organ dysfunction including requirement for dialysis, mechanical ventilation, or oxygen supplementation exceeding 40% FiO2 within 7 days of enrollment
- Significant liver disease evidenced by direct bilirubin >2 mg/dl or ALT or AST >5 times the upper limit of normal
- Creatinine clearance or estimated glomerular filtration rate <30 ml/min as calculated by institutional practice
- A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment
- Patients who are pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Steroid Taper
All enrolled patients start on the same dose of steroids for treatment of GVHD, blood samples are taken at week 1 and 2 post study start and biomarkers plus clinical response determines how steroid treatment is continued
|
Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of CR, VGPR, or PR on day 28 with low cumulative steroid exposure
Time Frame: study day 28
|
Proportion of patients with low-risk GVHD (Minnesota standard risk/Ann Arbor 1) who are in CR, VGPR or PR on day 28 and whose cumulative prednisone (or other steroid equivalent) exposure during the first four weeks of treatment is ≤13.5 mg/kg and who have had no intervening additional GVHD therapy for those in CR or VGPR. Complete Response (CR): All evaluable organs (skin, liver, GI tract) stage 0. Very Good Partial Response (VGPR): Any response that approximates a CR with the exception of rash <25% body surface area. Partial Response (PR): An improvement in one or more organ involved with GVHD symptoms without worsening in others. |
study day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment response by day 28
Time Frame: study day 28
|
Proportion of patients who achieve a treatment response by day 28 of treatment.
Treatment responses are defined as complete response (CR), very good partial response (VGPR), or partial response (PR).
For a response to be scored as CR, VGPR, or PR on day 28, the patient must be in response on day 28 and have had no intervening systemic therapy for acute GVHD other than steroids.
|
study day 28
|
Serious infection rate
Time Frame: study day 90
|
Proportion of patients who develop serious infections (viral, bacterial, fungal, parasitic as defined in protocol) Serious infections are defined using the standardized criteria widely used for clinical trials at academic BMT centers, such as life-threatening fungal infections or hemorrhagic cystitis from BK viral infection and include clinically significant CMV infections that require anti-viral treatment regardless of end-organ damage, given the toxicity of such treatments. Serious infections include any viral, bacterial, fungal or parasitic infections that requires systemic treatment. |
study day 90
|
Overall survival at 6 months
Time Frame: 6 months
|
Overall survival at 6 months OS is defined as the time from the first dose of study treatment to the date of death (whatever the cause). |
6 months
|
Overall survival at 12 months
Time Frame: 12 months
|
Overall survival at 12 months OS is defined as the time from the first dose of study treatment to the date of death (whatever the cause). |
12 months
|
Cumulative incidence of Non-Relapse Mortality (NRM) at 6 months
Time Frame: 6 months
|
Cumulative incidence of NRM at 6 months Survival will be tracked during the study, any deaths will be collected. Any death that occurs after hematopoietic stem cell transplantation (HCT) not attributable to relapse of the underlying disease will be considered a non-relapse death. |
6 months
|
Cumulative incidence of Non-Relapse Mortality (NRM) at 12 months
Time Frame: 12 months
|
Cumulative incidence of NRM at 12 months Survival will be tracked during the study, any deaths will be collected. Any death that occurs after HCT not attributable to relapse of the underlying disease will be considered a non-relapse death. |
12 months
|
Relapse rate at 6 months
Time Frame: 6 months
|
Relapse rate at 6 months Relapse, including date of relapse, of the underlying malignancy will be reported. |
6 months
|
Relapse rate at 12 months
Time Frame: 12 months
|
Relapse rate at 12 months Relapse, including date of relapse, of the underlying malignancy will be reported. |
12 months
|
Cumulative incidence of chronic GVHD
Time Frame: 12 months
|
Cumulative incidence of chronic GVHD requiring systemic steroid treatment by one year from enrollment
|
12 months
|
Cumulative steroid dose at study day 28
Time Frame: study day 28
|
Cumulative steroid dose at day 28 Steroid drug and dose is collected weekly for the first 4 weeks of study. |
study day 28
|
Cumulative steroid dose at study day 90
Time Frame: study day 90
|
Cumulative steroid dose at day 90 Steroid drug and dose is collected weekly for the first 4 weeks of study, and bi-weekly through study day 90. |
study day 90
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John E Levine, MD, MS, Icahn School of Medicine at Mount Sinai
- Principal Investigator: Muna Qayed, MD, MS, Children's Healthcare of Atlanta, Emory University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 21-0541
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adverse Effects
-
The Second Affiliated Hospital of Dalian Medical...CompletedAdverse EffectsChina
-
National Taiwan University HospitalDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
International Centre for Diarrhoeal Disease Research...Sanofi Pasteur, a Sanofi CompanyCompleted
-
Minamihanno HospitalCompleted
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Glostrup University Hospital, CopenhagenCompletedAnaesthesia | Adverse EffectsDenmark
-
The Second Affiliated Hospital of Hainan Medical...RecruitingAdverse Effects | Intubation, IntratrachealChina
-
Izmir Ataturk Training and Research HospitalNot yet recruitingPsychotropic Agents Causing Adverse Effects in Therapeutic Use | Anticholinergic Adverse Reaction | Anticholinergic Syndrome | Antiarrhythmic Drug Adverse Reaction | Antiparkinsonism Drugs Causing Adverse Effects in Therapeutic Use | Antispasmodic Adverse Reaction
-
NovartisCompletedKidney Transplantation | Adverse EffectsSwitzerland
-
Cedars-Sinai Medical CenterNational Institute on Aging (NIA)Not yet recruitingMedication Adverse Effects
Clinical Trials on Prednisone
-
Merck KGaA, Darmstadt, GermanyCompleted
-
University of South FloridaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingVasculitis | Granulomatosis With Polyangiitis | Wegener GranulomatosisUnited States
-
Rabin Medical CenterUnknown
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS)CompletedMyasthenia GravisThailand, Canada, Germany, Italy, Netherlands, Brazil, United States, Argentina, Australia, Chile, Japan, Mexico, Poland, Portugal, South Africa, Spain, Taiwan, United Kingdom
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingGranulomatosis With PolyangiitisUnited States, Canada
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknown
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain
-
Prof. Tony hayek MDCompletedDiabetes | Atherosclerosis | DyslipidemiasIsrael
-
Health Science Center of Xi'an Jiaotong UniversityUnknownFocal Segmental GlomerulosclerosisChina
-
National Institute for Tuberculosis and Lung Diseases...SuspendedInterstitial Lung Disease | Lung Neoplasm MalignantPoland